Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on outcomes the biotech plans to use as co-primary endpoints in a registrational trial.